ReviewMedicina (Kaunas, Lithuania)2022
New Innovations for the Treatment of Vulvovaginal Atrophy: An Up-to-Date Review.
Review in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- The effects of various therapies on vulvovaginal atrophy and quality of life in gynecological cancer patients: a systematic review.Archives of gynecology and obstetrics · 2024Pooled it
- Managing Vulvovaginal Atrophy, in Postmenopausal Women, Without Hormones: Efficacy of a Hyaluronic Acid Vaginal Moisturizer.Healthcare (Basel, Switzerland) · 2026Article
- Anatomical and Patient-Reported Outcomes After Non-Ablative Er:YAG Laser Therapy for Genitourinary Syndrome of Menopause: A Prospective Real-World Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Electrotherapy Plus Photobiostimulation for the Treatment of Mild Pelvic Organ Prolapse and Stress Urinary Incontinence.Journal of clinical medicine · 2026Article
- Diode Laser and Radiofrequency for Genitourinary Syndrome of Menopause: A Comparative Analysis.Healthcare (Basel, Switzerland) · 2026Article
- Sexual function in chronic illness and cancer perspectives of the patient, partner, and healthcare provider; innovations; and updates: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024).Sexual medicine reviews · 2026Review
- Laser and Energy-Based Devices in Aesthetic Practice: A 10-Year Single-Surgeon Review of Treatments, Complications, and Same-Practice Surgical Crossover.Aesthetic surgery journal. Open forum · 2026Article
- Histopathological Verification of Abnormal Cytology Results Suggesting High-Grade Intraepithelial Lesions in Women over 50 Years of Age-Evaluation of the Clinical Utility of Conventional Gynecological Cytology.Journal of clinical medicine · 2025Article
- Development of a Vaginal Extracellular Matrix Hydrogel for Combating Genitourinary Syndrome of Menopause.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Gut Microbiome and Estrogen.Journal of menopausal medicine · 2025Review
- Thermo-Ablative Fractional COMedical sciences (Basel, Switzerland) · 2025Article
- Investigation ofFrontiers in pharmacology · 2025Article
- Short-term oral estriol for cervical stenosis, labial adhesion, and challenging intrauterine contraceptive device removal in postmenopausal women: A case series.SAGE open medical case reports · 2025Article
- Efficacy of transvaginal erbium laser treatment for vaginal relaxation and its impact on vaginal microenvironment indicators.American journal of translational research · 2025Article
- From diagnosis to survivorship addressing the sexuality of women during cancer.The oncologist · 2024Review
- Treatment of Genitourinary Syndrome of Menopause in Breast Cancer and Gynecologic Cancer Survivors: Retrospective Analysis of Efficacy and Safety of Vaginal Estriol, Vaginal Dehydroepiandrosterone and Ospemifene.Journal of menopausal medicine · 2024Article
- Managing sexual health challenges in breast cancer survivors: A comprehensive review.Breast (Edinburgh, Scotland) · 2024Review
- Understanding the Benefits of COMedicina (Kaunas, Lithuania) · 2024Article
- A Novel Method for the Measurement of the Vaginal Wall Thickness by Transvaginal Ultrasound: A Study of Inter- and Intra-Observer Reliability.Medicina (Kaunas, Lithuania) · 2024Article
- The Concept behind the Suitability of Menstrual Blood-Derived Stem Cells for the Management of Vaginal Atrophy among BRCA Mutation Carriers after RRSO.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvovaginal atrophy (VVA) is a chronic progressive disease involving the female genital apparatus and lower urinary tract. This condition is related to hypoestrogenism consequent to menopause onset but is also due to the hormonal decrease after adjuvant therapy for patients affected by breast cancer. Considering the high prevalence of VVA and the expected growth of this condition due to the increase in the average age of the female population, it is easy to understand its significant social impact. VVA causes uncomfortable disorders, such as vaginal dryness, itching, burning, and dyspareunia, and requires constant treatment, on cessation of which symptoms tend to reappear. The currently available therapies include vaginal lubricants and moisturizers, vaginal estrogens and dehydroepiandrosterone (DHEA), systemic hormone therapy, and Ospemifene. Considering, however, that such therapies have some problems that include contraindications, ineffectiveness, and low compliance, finding an innovative, effective, and safe treatment is crucial. The present data suggest great efficacy and safety of a vaginal laser in the treatment of genital symptoms and improvement in sexual function in patients affected by VVA. The beneficial effect tends to be sustained over the long-term, and no serious adverse events have been identified. The aim of this review is to report up-to-date efficacy and safety data of laser energy devices, in particular the microablative fractional carbon dioxide laser and the non-ablative photothermal Erbium-YAG laser.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.